Applications DHPLC Systems (e.g. WAVE Systems) can be used for a wide range of applications including: –Mutation Detection –Sizing –Oligonucleotide Purification and Analysis –Forensics –Microbial Analysis –RNA Isolation and Purification –Single Base Extension –Methylation
With the WAVE System you can: Scan fragments for both known and novel mutations/SNPs without extensive resequencing Detect low-abundance mutations in heterogeneous samples Enrich for low-abundance alleles Fractionate complex mixtures of related fragments based on differences in sequence content Perform targeted mutation/SNP scoring via primer extension assays Analyze end-point products from allele-specific Probe/Primer- based Amplification Technologies
Probe/Primer-based Amplification Technologies Primer-based Amplifications: –Non-Isothermal Amplifications e.g. PCR-based Methods –Isothermal Amplifications/Non-PCR-based Amplifications: –NASBA –HDA –SDA –, and more than 45 N.A.I.A. Technologies Probe-based Amplifications: –For example: Ligase Chain Reactions
CARTRIDGE dependent Applications e.g. via WAVE Systems Sizing and Mutation Detection DNA-99-3510 DNASep Cartridge 4.6 mm x 50 mm, for variety of DNA applications including Sizing and Mutation Detection, load capacity of 2µg especially for Rapid Mutation Detection DNA-99-3710 DNASep HT Cartridge 6.5 mm x 37 mm, for variety of DNA application but especially for Rapid Mutation Detection, load capacity of 4µg for Oligo Purification work only NUC-99-3550 OligoSep® Cartridge 4.6 mm x 50 mm; for Oligo Purification work only for Oligo Purification NUC-99-3860 OligoSep Prep HC Cartridge 7.8 mm x 50 mm, for Oligo Purification, load capacity of 5000µg for variety of RNA applications RNA-99-3810 RNASep® Prep Cartridge 7.8 mm x 50 mm, for variety of RNA applications, load capacity of 50µg total RNA -OR- 1000ng of specific RNA
Chromatograms and pedigree of patients 3 and 16. A. DHPLC analysis in normal control, patients 3 and 16. Both patients show abnormal DHPLC peak patterns with two peaks in comparison to normal control. B. Sequencing data in patient 3 and his family members. C. Sequencing data in patient 16 and his family members.